Lupin Limited has informed the Exchange regarding a press release dated July 16, 2025, titled "Lupin Launches Loteprednol Etabonate Ophthalmic Suspension, 0.5% in the United States".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin has launched a generic eye drop called Loteprednol Etabonate Ophthalmic Suspension, 0.5% in the US market. The product is a generic equivalent of Bausch & Lomb's branded drug Lotemax, which treats inflammatory eye conditions such as allergic conjunctivitis, iritis, and post-surgery eye inflammation. The reference brand Lotemax had estimated annual US sales of around USD 55 million (IQVIA MAT May 2025), representing the market opportunity Lupin is now tapping into. This adds another product to Lupin's growing US generic portfolio, where the company already has a strong presence across multiple therapy areas.
Modestly positive for shareholders — Lupin gains entry into a USD 55 million US ophthalmology market, adding to its US revenue base, though generic launches typically face pricing pressure and competition over time.